Medicine & Life Sciences
Liver Transplantation
100%
Hepacivirus
84%
Fibrosis
50%
End Stage Liver Disease
35%
Hepatitis C
32%
Ribavirin
26%
Liver
22%
Transplant Recipients
20%
Acute-On-Chronic Liver Failure
19%
Genotype
19%
Transplants
18%
Virus Diseases
18%
Tissue Donors
18%
Transplantation
15%
Liver Diseases
14%
Hepatorenal Syndrome
14%
Serum
14%
Blood Cells
14%
Chronic Hepatitis C
13%
Terlipressin
13%
Infections
12%
Recurrence
12%
Hepatic Encephalopathy
12%
GB virus C
12%
RNA
11%
Hepatitis
11%
Virus Replication
11%
Sustained Virologic Response
11%
Living Donors
10%
Interferons
10%
Simeprevir
10%
Survival
10%
Sofosbuvir
10%
Therapeutics
9%
Antiviral Agents
9%
Quasispecies
9%
Inpatients
9%
Hepatocellular Carcinoma
8%
Gastroenterology
8%
Mortality
8%
sofosbuvir drug combination ledipasvir
7%
Hepatopulmonary Syndrome
7%
Hepatitis B virus
7%
Multicenter Studies
6%
Hepatitis B
6%
Portal Hypertension
6%
Creatinine
6%
Acute Kidney Injury
6%
Placebos
5%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
5%